Stockscreener 앱 받기
41.43
5.26%
2.07
시간 외 거래:
41.66
0.23
+0.56%
전일 마감가:
$39.36
열려 있는:
$39.81
하루 거래량:
1.64M
Relative Volume:
1.04
시가총액:
$3.54B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-9.2685
EPS:
-4.47
순현금흐름:
$-191.20M
1주 성능:
+0.88%
1개월 성능:
-24.88%
6개월 성능:
-22.00%
1년 성능:
-37.28%
1일 변동 폭
$39.34
$41.44
1주일 범위
$38.20
$41.44
52주 변동 폭
$38.20
$91.10
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
41.43 | 3.54B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.76 | 104.50B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.19 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.16 | 37.08B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.62 | 30.13B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.30 | 27.64B | 3.30B | -501.07M | 1.03B | -2.1146 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - MSN
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up - Simply Wall St
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week LowWhat's Next? - MarketBeat
CRISPR Therapeutics stock hits 52-week low at $39.31 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics stock hits 52-week low at $39.31 - Investing.com
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $77.93 Consensus Price Target from Brokerages - MarketBeat
CRISPR Therapeutics Enters Oversold Territory (CRSP) - Nasdaq
February 2025 Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy - GlobeNewswire Inc.
Institutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year losses - Yahoo Finance
Geode Capital Management LLC Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
(CRSP) Trading Advice - Stock Traders Daily
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Yahoo Finance
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com
JMP Securities Reaffirms "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 1-Year LowTime to Sell? - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - MSN
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interest - MarketBeat
State Street Corp Acquires 599,304 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year LowShould You Sell? - MarketBeat
3 Things You Need To Know If You Buy CRISPR Therapeutics Today - Barchart
CRISPR Therapeutics stock hits 52-week low at $43.37 - Investing.com
Zacks Research Issues Negative Forecast for CRSP Earnings - MarketBeat
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? - Insider Monkey
Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares - GuruFocus.com
What is William Blair's Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Chardan Capital - MarketBeat
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
CRISPR's CTX112 Cancer Therapy Shows 67% Response Rate in Clinical Trial, Earns FDA Special Status - StockTitan
XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Main Management ETF Advisors LLC Purchases Shares of 14,744 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - AOL
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
자본화:
|
볼륨(24시간):